New York Valves 2025 - Early outcomes from an observational study with the PASCAL System show a 97% device success rate.

Dr Santiago Garcia (The Christ Hospital, Cincinnati, OH, US) joins us to discuss a novel TEER device system. This observational study investigated the use of the PASCAL Prescision system in over 2000 patients from the STS/ACC/TVT registry over a period of two years.

Findings showed a 97% device success rate. In addition, serious adverse events were uncommon (less than 1%), and safety events at 30 days were favourable.

Interview Questions:

1. Could you tell us about the PASCAL System?
2. What was the study design and patient population?
3. What are the key outcomes?
4. What are the potential clinical implications of these findings?
5. What further study is needed, and what are the next steps?

Recorded remotely from Cincinnati, 2025.

Editors: Yazmin Sadik, Jordan Rance
Videographer: David Ben-Harosh

Support: This is an independent interview produced by Radcliffe Cardiology.